Phase 1/1b Study of RG7388, a Potent MDM2 Antagonist, in Acute Myelogenous Leukemia (AML) Patients (Pts)
The DOI matches its Crossref record.
Abstract
Background: RG7388 is a new, potent, oral, nutlin-class MDM2 antagonist. This trial evaluated its use in AML to determine the recommended phase 2 dose (RP2D), dose-limiting toxicities (DLTs), pharmacokinetics (PK), pharmacodynamics and clinical responses. Methods: This multicenter, open-label phase 1/1b dose escalation (DE) study evaluated RG7388 as monotherapy (daily ´ 5 d q28d) (Part 1 DE) and in combination with cytarabine (ara-C 1 g/m2 IV x 6 d q28d) (Part 2 DE). Extensions (Ex) were initiated at the RP2D. Part 1Ex (RG7388) included pts > 70 y or > 60 y with comorbidities. Part 2Ex pts (RG7388 ± ara-C) had relapsed/refractory (R/R) AML, ≤ 2 regimens and no antecedent hematologic disorders (AHD) or transplant (ASCT). Blood and marrow analyses included PK, TP53 mutations (mt) by AmpliChip, serum MIC-1 and MDM2gene expression. Results: To date, 86 pts have been treated. DE is complete, Part 1Ex was discontinued after 9 pts and 34 of 40 planned pts are enrolled in Part 2Ex. One DLT of prolonged myelosuppression was reported. RP2D is 1200 mg/d (600 mg bid) x 5 d q28d for both mono- and combination therapy due to diarrhea not formally a DLT but felt to be dose-limiting. The most common adverse events were GI (diarrhea reported by > 85% of pts) or infection-related (> 70% of pts). Twenty pts received monotherapy during Part 1 DE at 400 (n = 2), 800 (n = 6) and 1600 mg (n = 12) daily x 5 d. Median age was 68.5 y (range 28-83 y), median prior therapies = 2 (range 0-4), 1 pt had ASCT and 8 had AHD. Four pts died in the first 30 days. Five pts achieved either a CR (n = 2) or CRi/MLFS (n = 3). In Part 1Ex, 9 pts were treated with RG7388 at the RP2D. Median age was 75 y (range 66-83), 8 pts had AHD (6 prior hypomethylators, 3 pts lower intensity therapy) and 1 had prior solid tumor. Best responses reported were 1 CRi/MLFS, 1 PR, 1HI, 3 PD. Three pts died in the first 30 days. Further enrollment in this arm was discontinued as induction of prolonged myelosuppression increased the risks of infection and early deaths. Combination treatment with lower RG7388 doses may be better tolerated in this fragile elderly population. Twenty-three pts were enrolled in Part 2 DE (RG7388 + ara-C) at daily doses of 400 (n = 10), 800 (n = 7), and 1200 mg (n = 6); median age 64 y (range 32-76); median prior therapies = 1.5 (range 0-5); prior ASCT 2; AHD 4; 5 had prior malignancies. Four pts died in the first 30 days. Six relapsed AML pts achieved CRs (4 received prior ara-C and 2 had prior hypomethylators). To date, 34 of 40 planned pts with R/R AML have been enrolled to Part 2Ex (RG7388 ± ara-C); 23 pts have responses reported, with 4 CRs, 1 CRi, 1 PR, 1 HI, 16 PD. Three pts died in the first 30 days. T1/2 is ≈ 1 d, irrespective of age, concomitant azoles or ara-C. Bone marrow levels are ≈ 70% of plasma drug levels at steady state. CRs were seen in diverse pts, including varied risk groups, prior AHD, therapy-related AML (t-AML), p53 mt, R/R and de novo AML. All pts who achieved a CR during DE were relapse free for > 60 d. One pt on monotherapy and 2 on combination therapy remained relapse free for > 400 d and > 200 d from start of study, respectively. A potential predictive gene expression signature correlated with RG7388 therapy (AUC = 0.73, p = 0.021). Conclusions: We report the Ph1/1b PK, safety and clinical activity of a new, potent MDM2 antagonist in AML. CRs occur rapidly and are durable (> 60 d) in elderly AML pts with RG7388 monotherapy and in R/R pts with combination therapy. Table Patient characteristics by response to treatment Part 1 DE (N = 20) 16 responses Best response 2 CR; 3CRi/MLFS 3 PR 4 HI 4 PD TP53 status WT WT 1 MT, 3 WT 1 V ELN* AHD(responders) 4 I, 1 A 3 (MDS, MF, CMML) 3 I 2 (MDS, CMML) Part 1Ex (N = 9) 6 responses Best response 1 CRi/MLFS 0 PR 2 HI 3 PD TP53 status WT WT, MT 2 WT, 1 U ELN* AHD(responders) I ET Part 2 DE (N = 23) 20 responses Best response 6 CR 2 PR 2 HI 10 PD TP53 status 1 MT WT WT 1 MT, 1 V ELN* AHD(responders) 1 F, 3 I, 2 A 1 t-AML 1 I, 1 A Part 2Ex (N = 34) 23 responses Best response 4 CR; 1 CRi/MLFS 1 PR 1 HI 16 PD TP53 status 4 WT, 1 U WT WT 1 MT, 5 WT, 10 U ELN*(responders) 1 F, 3 I, 1 A A CR, complete remission; CRi, complete remission with incomplete recovery; HI, hematologic improvement; MLFS, morphologic leukemia-free state; PD, progressive disease; PR, partial response; WT, wild type; V, splice variant; U, unknown/pending; AHD, includes myelodysplastic syndrome (MDS), essential thrombocythemia (ET), chronic myelomonocytic leukemia (CMML), myelofibrosis(MF) *ELN: Risk by European Leukemia Net: favorable (F), Intermediate I and II (I), or adverse (A) Disclosures: Yee: Roche: Research Funding. Martinelli:Pfizer: Consultancy, Speakers Bureau; BMS: Consultancy, Speakers Bureau; Novartis: Consultancy, Speakers Bureau; ARIAD: Consultancy, Speakers Bureau. Vey:Roche: Honoraria. Assouline:Roche: Honoraria, Research Funding; Janssen: Honoraria. Drummond:Novartis: Consultancy, Honoraria, Speakers Bureau; Celgene: Consultancy, Honoraria, Speakers Bureau. Blotner:Roche: Employment. Higgins:Roche: Employment. Middleton:Roche: Employment. Nichols:Roche: Employment. Chen:Roche: Employment. Zhong:Roche: Employment. Pierceall:Roche: Employment. Zhi:Roche: Employment. Chen:Roche: Employment.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Tumor suppressor p53: Biology, signaling pathways, and therapeutic targeting
Hernández Borrero, L. J., & El-Deiry, W. S. (2021) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2021.188556 · Cited by 748
MDM2 inhibition: an important step forward in cancer therapy
Konopleva, M., Martinelli, G., Daver, N., Papayannidis, C., Wei, A., Higgins, B., Ott, M., Mascarenhas, J., & Andreeff, M. (2020) · Leukemia · doi:10.1038/s41375-020-0949-z · Cited by 376
Self-citationZhu, H., Gao, H., Ji, Y., Zhou, Q., Du, Z., Tian, L., Jiang, Y., Yao, K., & Zhou, Z. (2022) · Journal of Hematology & Oncology · doi:10.1186/s13045-022-01314-3 · Cited by 223
“A clinical study of RG7388 also showed similar phenomenon, with no obvious p53 activation and serious dose-dependent side effects [88].”
BackgroundGluck, W. L., Gounder, M. M., Frank, R., Eskens, F., Blay, J. Y., Cassier, P. A., Soria, J.-C., Chawla, S., de Weger, V., Wagner, A. J., et al. (2020) · Investigational New Drugs · doi:10.1007/s10637-019-00840-1 · Cited by 127
Reis, B., Jukofsky, L., Chen, G., Martinelli, G., Zhong, H., So, W. V., Dickinson, M. J., Drummond, M., Assouline, S., Hashemyan, M., et al. (2016) · Haematologica · doi:10.3324/haematol.2015.139717 · Cited by 91
“Trial NP28679 (NCT01773408) is a phase 1/1b study evaluating idasanutlin treatment (monotherapy or in combination with cytarabine) in relapsed or refractory AML patients.(7) Safety and pharmacokinetics were primary endpoints, with clinical response as a secondary endpoint.”
BackgroundSelf-citation
Metadata
- Authors
- Yee, K., Martinelli, G., Vey, N., Dickinson, M. J., Seiter, K., Assouline, S., Drummond, M., Yoon, S.-S., Kasner, M., Lee, J.-H., Kelly, K. R., Blotner, S., Higgins, B., Middleton, S., Nichols, G., Chen, G., Zhong, H., Pierceall, W. E., Zhi, J., & Chen, L.-C.
- Venue
- Blood
- Publisher
- American Society of Hematology
- Published
- 2014-12-06
- Volume
- 124
- Issue
- 21
- Pages
- 116-116
- ISSN
- 0006-4971 (ISSN-L)
- 1528-0020
- OpenAlex
- W2523237690
- Cited by
- 76
- References
- 0
- FWCI
- 2.45
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Phase 1/1b Study of RG7388, a Potent MDM2 Antagonist, in Acute Myelogenous Leukemia (AML) Patients (Pts). https://app.cochat.ai/papers/10.1182/blood.v124.21.116.116
- The paper
- Yee, K., Martinelli, G., Vey, N., Dickinson, M. J., Seiter, K., Assouline, S., Drummond, M., Yoon, S.-S., Kasner, M., Lee, J.-H., Kelly, K. R., Blotner, S., Higgins, B., Middleton, S., Nichols, G., Chen, G., Zhong, H., Pierceall, W. E., Zhi, J., & Chen, L.-C. (2014). Phase 1/1b Study of RG7388, a Potent MDM2 Antagonist, in Acute Myelogenous Leukemia (AML) Patients (Pts). Blood. https://doi.org/10.1182/blood.v124.21.116.116
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.